北海道大学 · Engineering
마에키 마사토시 교수의 연구실은 주로 나노의학 및 약물 전달 시스템 분야에서 활동하며, 특히 리피드 나노입자(LNP)의 정밀한 크기 제어와 구조 제어를 핵심 연구 방향으로 삼고 있습니다. 마이크로플루이딕 장치를 활용한 연속적이고 스케일업 가능한 LNP 제조 기술 개발을 통해 암세포 표적성 향상과 유전자 약물의 효율적 전달을 목표로 하고 있습니다. 또한, 리포좀의 라멜라 구조, 막 유동성, 약물 부착도 등 물리화학적 특성의 제어를 통해 약물의 생체 내 행동을 정밀하게 조절하는 데에도 기여하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
The precise size control of the lipid nanoparticle (LNP)-based nanodrug delivery system (DDS) carriers, such as 10 nm size tuning of LNPs, is one major challenge for the development of next-generation nanomedicines. Size-controlled LNPs would realize size-selective tumor targeting and deliver DNA and RNA to target tumor tissues effectively by passing through the stromal cells. Herein, we developed a baffle mixer device named the invasive lipid nanoparticle production device, or iLiNP device for
Lipid nanoparticles (LNPs) or liposomes are the most widely used drug carriers for nanomedicines. The size of LNPs is one of the essential factors affecting drug delivery efficiency and therapeutic efficiency. Here, we demonstrated the effect of lipid concentration and mixing performance on the LNP size using microfluidic devices with the aim of understanding the LNP formation mechanism and controlling the LNP size precisely. We fabricated microfluidic devices with different depths, 11 μm and 31
Formation behavior was discussed for lipid nanoparticles (LNPs) in the microfluidic devices equipped with different cycle numbers of the micromixers.
Microfluidic methodologies for preparation of lipid nanoparticles (LNPs) based on an organic solvent injection method enable precise size control of the LNPs. After preparation of LNPs, the organic solvent injection method needs some post-treatments, such as overnight dialysis or direct dilution with a buffer solution. LNP production using the microfluidic-based organic solvent injection method is dominated by kinetics rather than thermodynamics. Kinetics of ethanol removal from the inner and ou
Microfluidic devices are widely used in lipid nanoparticle (LNP)-based vaccines and nanomedicine research. These devices should be stiff enough to withstand the high flow rate for the mass production of LNPs, and malleable enough to use when fabricating complicated microchannel or micromixer structures, such as staggering herringbone micromixers. Due to the limitations of the available fabrication methods, optimal microfluidic devices have not yet been developed. In this study, we report the dev
The function of liposomal drugs and cosmetics is not only controlled by the lipid composition/formulation, but also by the liposome size and internal structure/properties (uni- and multi-lamellae) and membrane rigid/fluidic properties. Although the preparation of liposomes using microfluidic devices offers precise size control and easy scale-up in a continuous manufacturing system, their lamellarity and physicochemical property differences have not been investigated. We therefore prepared differ
Herein, we demonstrate the potential of droplet-based microfluidics for controlling protein crystallization and generating single-protein crystals. We estimated the critical droplet size for obtaining a single crystal within a microdroplet and investigated the crystallization of four model proteins to confirm the effect of protein molecular diffusion on crystallization. A single crystal was obtained in microdroplets smaller than the critical size by using droplet-based microfluidics. In the case
Sub 100 nm-sized lipid nanoparticles (LNPs) have been widely used in drug delivery systems (DDSs). The size of the LNPs is an important parameter for the DDS performance, such as biodistribution and gene silencing using siRNAs. However, the LNPs prepared by the conventional preparation method show a wide size distribution. To improve the LNP size distribution, we developed a microfluidic device, named the iLiNP™ device, in a previous study. This device could produce LNPs in the size range of 20
Room-temperature (RT) protein crystallography provides significant information to elucidate protein function under physiological conditions. In particular, contrary to typical binding assays, X-ray crystal structure analysis of a protein-ligand complex can determine the three-dimensional (3D) configuration of its binding site. This allows the development of effective drugs by structure-based and fragment-based (FBDD) drug design. However, RT crystallography and RT crystallography-based protein-l
Protein crystallization and subsequent X-ray diffraction analysis of the three-dimensional structure are necessary for elucidation of the biological functions of proteins and effective rational drug design. Therefore, controlling protein crystallization is important to obtain high resolution X-ray diffraction data. Here, a simple microfluidic method using chips with 10 and 50 μm high crystallization chambers to selectively form suitable single protein crystals for X-ray analysis is demonstrated.
The preparation of lipid-based nanoparticles (LNPs) using microfluidic devices offers significant advantages, such as precise size control and easy scale-up, in a continuous manufacturing system. However, improvements in this preparation method are needed to enhance LNP productivity to meet commercial, such as clinical and consumer, demands. Feeding a highly concentrated lipid solution into microfluidic devices to obtain a high concentration of LNPs is one of the ways to boost productivity. Howe
